MedTrace Logo

Activated Protein C and Microcirculation

NCT01806428 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2013-10-22

No results posted yet for this study

Summary

Objective: to test the hypothesis that recombinant activated protein C (aPC) therapy improves the microcirculation of severe septic patients.

Design: Prospective, open study. Setting: University 12-beds intensive care unit. Patients: Septic patients with at least two sepsis-induced organ failures occurring within 48 hours of the onset of sepsis were included in a one year period.

Interventions: Patients who had no contraindication to aPC administration received aPC at a dose of 24 mcg/kg/h for 96 hours. Patients with contraindications to aPC infusion were considered as controls.

Conditions

  • Severe Sepsis
  • Septic Shock

Sponsors & Collaborators

  • Azienda Ospedaliero, Universitaria Ospedali Riuniti

    collaborator OTHER

  • Università Politecnica delle Marche

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2010-12-31
Completion
2011-08-31

Countries

  • Italy

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01806428 on ClinicalTrials.gov